CROWN: ctDNA Analyses Help Predict Early Progression With First-Line Lorlatinib in ALK+ NSCLC
Exploratory analyses of the phase 3 CROWN trial presented at the 2026 ESMO Congress found that baseline and on-treatment ctDNA features, including TP53 mutations, were linked to early progression or prolonged PFS with first-line lorlatinib in ALK-positive NSCLC. Early progressors had more altered genes and TP53 mutations. Undetectable tumor fraction at baseline and its clearance by week 4 were associated with longer PFS.
How this was made
The 30-second read
Why it matters
The data could influence analyst forecasts for Pfizer's oncology revenue and affect pricing expectations for lorlatinib.
Market read
First disclosure of predictive ctDNA biomarkers for a major lung‑cancer therapy, potentially shifting market sentiment on Pfizer's oncology pipeline.
What to watch
Exclusion of Chinese patients and small sample size could limit the generalizability of the findings.
Background
The CROWN trial compares lorlatinib to crizotinib as first‑line therapy for ALK‑positive NSCLC. The presented ctDNA analysis adds a new layer of predictive insight.
Ticker impact
New ctDNA analyses from the phase‑3 CROWN trial presented at ESMO 2026 show predictive biomarkers for early progression on lorlatinib, potentially influencing investor perception of Pfizer's lung‑cancer portfolio.
likely modest upside as market prices in improved efficacy signals
First‑time disclosure of robust biomarker correlation; no new drug approval but strengthens existing product narrative.
Market effects
Strengthens the oncology/targeted‑therapy segment, may prompt re‑rating of competing ALK inhibitors.
US biotech and pharma stocks could see modest gains on broader oncology optimism.
Highlights the role of liquid biopsy in drug development, relevant to global precision‑medicine investors.
Counterpoint
Biomarker data may not translate into commercial advantage if competitors launch superior agents or if reimbursement remains uncertain.
Key entities
- CompanyPfizer Inc.
Manufacturer of lorlatinib (Lorbrena) and crizotinib (Xalkori).
- CompanyGuardant Health
Provider of the Guardant Infinity ctDNA assay used in the study.
